Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2001 1
2002 4
2003 1
2004 1
2006 1
2008 1
2009 2
2010 3
2012 2
2013 3
2014 3
2015 2
2016 1
2017 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Scully M, et al. Among authors: zeldin rk. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Free article. Clinical Trial.
Reply: To PMID 24388010.
Bergmann KC, Demoly P, Abiteboul K, Zeldin RK. Bergmann KC, et al. Among authors: zeldin rk. J Allergy Clin Immunol. 2015 Jan;135(1):288-9. doi: 10.1016/j.jaci.2014.09.021. Epub 2014 Oct 28. J Allergy Clin Immunol. 2015. PMID: 25441297 No abstract available.
Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Kaplan AP, et al. Among authors: zeldin rk. J Allergy Clin Immunol. 2008 Sep;122(3):569-73. doi: 10.1016/j.jaci.2008.07.006. J Allergy Clin Immunol. 2008. PMID: 18774392 Clinical Trial.
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK. Peyvandi F, et al. Among authors: zeldin rk. J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5. J Thromb Haemost. 2017. PMID: 28445600 Free article. Clinical Trial.
25 results